Welcome
“May all be happy, may all be healed, may all be at peace and may no one ever suffer."
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- U
- V
- W
- X
- Y
- Z
Post-menopausal osteoporosis - Generics
Post-menopausal osteoporosis is a common condition in women that results in low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fractures. Osteoporosis is often called the "silent disease" because it progresses slowly and has no symptoms until a fracture occurs. Fractures of the hip, wrist, and spine are the most common and can lead to significant disability, loss of independence, and reduced quality of life.
Risk factors for post-menopausal osteoporosis include advanced age, female gender, early menopause, family history of osteoporosis, low body weight or thin build, sedentary lifestyle, smoking, excessive alcohol consumption, and certain medical conditions such as rheumatoid arthritis, hyperthyroidism, and gastrointestinal disorders that interfere with calcium absorption.
Treatment for post-menopausal osteoporosis includes lifestyle modifications, such as regular weight-bearing exercise, a balanced diet rich in calcium and vitamin D, and smoking cessation. Additionally, medications may be prescribed to slow or halt bone loss and reduce the risk of fractures. Some of the medications include bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs).
Bisphosphonates are the most commonly used medications for osteoporosis. They work by slowing down the rate of bone loss, increasing bone density, and reducing the risk of fractures. Examples of bisphosphonates include alendronate, risedronate, ibandronate, and zoledronic acid.
Denosumab is a monoclonal antibody that targets a protein called RANK ligand, which plays a key role in bone resorption. By inhibiting RANK ligand, denosumab reduces bone loss, increases bone density, and reduces the risk of fractures.
Teriparatide is a synthetic form of parathyroid hormone that stimulates new bone growth and increases bone density. It is usually prescribed for patients with severe osteoporosis who have a high risk of fracture.
SERMs are medications that mimic the effects of estrogen on bone tissue. They increase bone density and reduce the risk of fractures, but they also have a protective effect against breast cancer. Raloxifene is an example of a SERM that is approved for the treatment of osteoporosis.
In conclusion, post-menopausal osteoporosis is a common condition that affects millions of women worldwide. It can lead to significant disability, loss of independence, and reduced quality of life. However, with early diagnosis and appropriate treatment, the risk of fractures can be reduced, and quality of life can be improved. If you are at risk for osteoporosis or have already been diagnosed with the condition, it is important to work closely with your healthcare provider to develop a comprehensive treatment plan that includes lifestyle modifications and appropriate medications.
Spermatogenesis induction
Liver cirrhosis
Keratosis
Psychotic disorders
Down Syndrome
Extrapyramidal symptoms
Actinic keratosis
Urothelial toxicity
Post menopausal osteoporosis, মেনোপৌসাল অস্টিওপোরোসিস
To be happy, beautiful, healthy, wealthy, hale and long-lived stay with DM3S.